Indonesia's Healthcare Sector to Gain Independence with New Plasma Fractionation Facility

Strategic Collaboration and Technology Transfer

A groundbreaking collaboration between SK Plasma, a subsidiary of SK Group, and Indonesia Investment Authority (INA) is set to revolutionize Indonesia's healthcare landscape. The joint venture, PT SKPlasma Core Indonesia, is establishing the country's first plasma fractionation facility in Karawang, West Java. This state-of-the-art facility is expected to commence commercial operations by the end of 2026 and will significantly enhance Indonesia's healthcare sovereignty.

Addressing Current Healthcare Challenges

Currently, Indonesia discards approximately 200,000 liters of plasma annually due to the lack of fractionation capabilities. This results in a heavy reliance on imported Plasma-Derived Therapeutic Products (PDTP), increasing healthcare costs and posing risks during health crises. The new facility will address this gap by producing essential therapies such as immunoglobulin, albumin, and coagulation factors.

Key Features of the Facility

1. GMP-certified operations: The facility will implement Good Manufacturing Practices (GMP) as per Korean standards, ensuring international quality compliance.
2. Advanced technology: Incorporating automation and digital systems commonly used in global biopharmaceutical manufacturing.
3. Cold chain and traceability: Features supporting international GMP standards for plasma-derived products.
4. Capacity building: Training programs for Indonesian workers, with 16 workers already receiving training in Korea.

Economic and Healthcare Impact

The facility is expected to create thousands of jobs for Indonesians and stimulate local economic growth. By producing PDTP domestically, Indonesia will reduce its dependence on international suppliers, potentially lowering healthcare costs and improving patient outcomes. The project also represents a significant step in Indonesia's healthcare infrastructure development, aligning with national health security objectives.

Implementation Timeline

• 2025: Ongoing construction (98% completion) and technology transfer initiation.
• 2026: Commercial operations expected to begin.
• 2027: Full-scale production of PDTP.

This strategic investment in healthcare infrastructure demonstrates Indonesia's commitment to improving its healthcare system and achieving greater self-sufficiency in medical supplies.